Breast cancer is a disease of women due to the actions of estrogens (E) and progesterone (P). While oophorectomy is protective, hormone replacement therapy with E+P increases breast cancer risk compared to E-only. This implicates P, either alone or with E, in tumor promotion. Though many studies address the actions of E or P alone, we contend that one must understand how these two hormones work together. E and P activate estrogen (ER) or progesterone (PR) receptors. Two PR isoforms, PR-A and PR-B, are equal in the normal breast but dysregulated in cancers. Tamoxifen treated patients whose tumors are PR-A rich relapse faster than patients with PR-B rich tumors. Importantly, PR-A and PR-B differentially influence E-dependent tumor growth in either the presence or absence of P. We postulate that PR-A and PR-B in the absence or presence of P, differentially influence effects of E and ER on tumors and that PR-A are especially harmful.
AIM 1. Mechanisms of ligand dependent (LD) and ligand independent (LI) transcription by PR.A vs. PR-B. In the presence of P, PR-A and PR-B exert different effects on gene transcription with PR-B more powerful. In the absence of P, PR-A and PR-B are also different with PR-A more powerful. We also show that in addition to Progesterone Response Elements (PRE), LD and LI PR-regulated promoters contain co-Response elements (coRE).
This aim dissects the role of PRE and coRE in differential gene regulation by PR-A and PR-B, and addresses mechanisms of LI gene regulation.
AIM 2. PR isoforms and in vivo LI and LD effects on E regulated tumor biology and therapeutics. Our preliminary data, using ER+, E-dependent xenografts in ovariectomized non-P supplemented mice, show that presence of PR-A suppresses tumor growth.
This aim asks: Why are PR-A+ tumors smaller than PR-B+ ones? How do PR influence tumor responses to antiestrogens? Why do PR block apoptosis by Taxanes? AIM 3. The role of ER and PR and their hormones in breast cancer cell metastasis and growth. Metastasis of ER+, PR+ breast cancers is the major killer of women yet conventional """"""""wisdom"""""""" holds that such tumors do not metastasize. Our models show metastasis of ER+, PR+ tumors.
This aim develops new models of E-dependent ER+, PR+ metastatic breast cancer and defines the role of steroid receptors and hormones in this process. In sum, we will develop new models to test the hypothesis that PR, even in the absence of P, modify ER+ tumor cell behavior, and that PR-A increase tumor aggressiveness and are harmful.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA026869-29
Application #
7321111
Study Section
Molecular and Cellular Endocrinology Study Section (MCE)
Program Officer
Sathyamoorthy, Neeraja
Project Start
1979-12-01
Project End
2009-11-30
Budget Start
2007-12-01
Budget End
2008-11-30
Support Year
29
Fiscal Year
2008
Total Cost
$398,776
Indirect Cost
Name
University of Colorado Denver
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Abdel-Hafiz, Hany A; Dudevoir, Michelle L; Perez, Daniel et al. (2018) SUMOylation Regulates Transcription by the Progesterone Receptor A Isoform in a Target Gene Selective Manner. Diseases 6:
Abdel-Hafiz, Hany A; Horwitz, Kathryn B (2015) Role of epigenetic modifications in luminal breast cancer. Epigenomics 7:847-62
Ogba, Ndiya; Manning, Nicole G; Bliesner, Brian S et al. (2014) Luminal breast cancer metastases and tumor arousal from dormancy are promoted by direct actions of estradiol and progesterone on the malignant cells. Breast Cancer Res 16:489
Pinto, Mauricio P; Dye, Wendy W; Jacobsen, Britta M et al. (2014) Malignant stroma increases luminal breast cancer cell proliferation and angiogenesis through platelet-derived growth factor signaling. BMC Cancer 14:735
Knox, Aaron J; Scaling, Allison L; Pinto, Mauricio P et al. (2014) Modeling luminal breast cancer heterogeneity: combination therapy to suppress a hormone receptor-negative, cytokeratin 5-positive subpopulation in luminal disease. Breast Cancer Res 16:418
Abdel-Hafiz, Hany A; Horwitz, Kathryn B (2014) Post-translational modifications of the progesterone receptors. J Steroid Biochem Mol Biol 140:80-9
Jambal, Purevsuren; Badtke, Melanie M; Harrell, J Chuck et al. (2013) Estrogen switches pure mucinous breast cancer to invasive lobular carcinoma with mucinous features. Breast Cancer Res Treat 137:431-48
Harvell, Djuana M E; Kim, Jihye; O'Brien, Jenean et al. (2013) Genomic signatures of pregnancy-associated breast cancer epithelia and stroma and their regulation by estrogens and progesterone. Horm Cancer 4:140-53
Haughian, James M; Pinto, Mauricio P; Harrell, J Chuck et al. (2012) Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch. Proc Natl Acad Sci U S A 109:2742-7
Abdel-Hafiz, Hany A; Horwitz, Kathryn B (2012) Control of progesterone receptor transcriptional synergy by SUMOylation and deSUMOylation. BMC Mol Biol 13:10

Showing the most recent 10 out of 88 publications